Avidity Biosciences (RNA) said Monday it completed enrollment in the biomarker group in a phase 1/2 trial of delpacibart braxlosiran, or del-brax, in people with facioscapulohumeral muscular dystrophy, a genetic muscle disorder.
The company said 51 participants were enrolled in the biomarker group.
The del-brax biomarker group was designed for a potential accelerated approval in the US, Avidity said, adding it plans to release a regulatory update in Q2.
The company's shares were down 6% in recent trading.
Price: 29.69, Change: -1.91, Percent Change: -6.04
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。